EICHOR
● Active Not Recruiting
A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
Condition: Retinitis Pigmentosa · Sponsor: Ocugen
About this study
This is a Phase 3 study to Assess the Efficacy, Safety and Tolerability of OCU400 in patients with retinitis pigmentosa (RP) associated with RHO mutations and patients with any other RP associated mutation with a clinical phenotype of RP. This is a multicenter, assessor blinded and randomized study which will enroll 140 subjects. Study has completed enrollment of all 140 subjects.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (17)
| Associated Retina Consultants | Phoenix, Arizona, United States | — |
| University of Southern Califormia | La Jolla, California, United States | — |
| University of Southern California, Roski Eye Insitute | Los Angeles, California, United States | — |
| Advanced Research, LLC. | Deerfield Beach, Florida, United States | — |
| Bascom Palmer Eye Institute, University of Miami, Miller School of Medicine | Miami, Florida, United States | — |
| Erie Retina Research LLC | Erie, Pennsylvania, United States | — |
| Vanderbilt Eye Institute | Nashville, Tennessee, United States | — |
| Retina Consultants of Texas | Bellaire, Texas, United States | — |
| Retina Foundation of the Southwest | Dallas, Texas, United States | — |
| Baylor College of Medicine | Houston, Texas, United States | — |
| Valley Retina Institute | McAllen, Texas, United States | — |
| Gundersen Health System | La Crosse, Wisconsin, United States | — |
+ 5 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.